Cart
sales@molnova.com
TAK-931
CAS No. 1330782-76-7
TAK-931( Simurosertib | TAK931 )
Catalog No. M11316 CAS No. 1330782-76-7
TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 160 | In Stock |
|
| 5MG | 154 | In Stock |
|
| 10MG | 215 | In Stock |
|
| 25MG | 399 | In Stock |
|
| 50MG | 551 | In Stock |
|
| 100MG | 762 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAK-931
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
-
DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM; prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis, demonstrates antiproliferative activity with cancer cell lines and tumor growth inhibition (TGI) in murine ectopic xenograft models. Colon Cancer,Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsSimurosertib | TAK931
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationColon Cancer
Chemical Information
-
CAS Number1330782-76-7
-
Formula Weight341.433
-
Molecular FormulaC17H19N5OS
-
Purity>98% (HPLC)
-
SolubilityDMSO : 75 mg/mL 219.66 mM
-
SMILESO=C1C2=C(C=C(C3=CNN=C3C)S2)N=C([C@H]4N(CC5)CCC5C4)N1
-
Chemical NameThieno[3,2-d]pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo[2.2.2]oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Charles Locuson, et al. Abstract 5041: Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor. AACR.
2. Kenichi Iwai, et al. Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931. AACR.
molnova catalog
related products
-
BAY 1251152
BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM.
-
P18IN003
P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of hematopoietic stem cells.
-
Cirtuvivint
Cirtuvivint (SM08502) is a potent, orally active CDC-like kinase (CLK) inhibitor useful for the study of arthritis.
